Fig. 7: The SETD8 inhibitor UNC0379, in combination with the Wee1 inhibitor adavosertib, impairs glioblastoma tumor growth in a xenograft mouse model.

a U251 glioblastoma cells were inoculated in CD1 mice. After 8 days, mice were randomized into four experimental groups and treated as indicated. b Tumor dimensions were measured using a digital caliper. Dimensions (V1) at each time point (D8–D21) were compared to dimensions at treatment start point (V0) to report tumor increase. All values are given as mean ± standard error among the seven animals in each group. Statistical analysis was performed using one-way ANOVA, followed by multiple t test. p value was referred to the DMSO-treated group. c At day 21 (end point of the experiment) tumor increase in mice treated with UNC0379 or adavosertib alone was compared to tumor increase in mice treated with UNC0379+adavosertib in combination. All values are given as mean ± standard deviation. Statistical analysis was performed using Student’s t test. d Tumor weight, upon excision at day 21, of control or UNC0379+adavosertib-treated mice. All values are given as mean ± standard deviation. Statistical analysis was performed using Student’s t test. e Tumor growth measured, upon luciferin injection, by IVIS in vivo imaging at the start (day 8) and at end (day 21) points of the treatment. Graphs show, at both time points, total flux of control, vehicle-treated mice compared to total flux of mice treated with UNC0379+adavosertib in combination. All values are given as mean ± standard deviation. Statistical analysis was performed using Student’s t test. On the left, representative images of one control and of one UNC0379+adavosertib-treated mouse. *** p < 0.001; ** p < 0.01; * p < 0.05.